Sabby Management, LLC Autolus Therapeutics PLC Transaction History

Sabby Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.52 - $5.46 $483,081 - $749,324	-137,239 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $830,081 - $1.14 Million	-162,761 Reduced 54.25%	137,239 $712,000
Q3 2021 Nov 15, 2021	SELL	$5.32 - $7.37 $532,266 - $737,368	-100,050 Reduced 25.01%	300,000 $1.97 Million
Q2 2021 Aug 16, 2021	SELL	$4.78 - $7.96 $598,360 - $996,432	-125,180 Reduced 23.83%	400,050 $2.66 Million
Q1 2021 May 17, 2021	BUY	$5.49 - $9.36 $2.88 Million - $4.92 Million	525,230 New	525,230 $3.01 Million

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.